DNA methylation and genotype specific biomarker for predicting post-traumatic stress disorder
AssigneesThe Johns Hopkins University, UMC Utrecht Holding B.V.
InventorsZachary Kaminsky, Marco Paul Maria Boks
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of biomarkers to predict post-traumatic stress disorder (PTSD). In one embodiment, a method for predicting PTSD in a subject comprises the steps of (a) measuring the DNA methylation level of a CpG dinucleotide in the 3′ untranslated region of SKA2; (b) identifying the genotype at a SNP within the 3′ UTR of SKA2, and (c) predicting PTSD in the subject using a prediction algorithm.
Claims7
A method for treating post-traumatic stress disorder (PTSD) in a subject comprising the step of administering a PTSD treatment to a subject predicted to have PTSD using a method comprising the steps of:
- (a) measuring DNA methylation level of a CpG dinucleotide located on the minus strand of chromosome 17, at position 57187729 from DNA isolated from a sample collected from the subject;
- (b) detecting the genotype at the single nucleotide polymorphism (SNP) rs7208505, from DNA isolated from a sample collected from the subject;
- and
- (c) using a linear model that incorporates the measured DNA methylation level and genotype at rs7208505, age and sex to predict PTSD in the subject,
- wherein the PTSD treatment comprises psychotherapy, antidepressants and/or anti-anxiety medication.
Dependencies are inferred from the claim text.